ABSTRACT
BACKGROUND: The explicit mechanism of erectile dysfunction caused by low androgen status is unknown. It was reported that eNOS was expressed in extracellular vesicles (EVs). Androgen may regulate erectile function by affect the release of EVs from endothelial cells. OBJECTIVES: To investigate whether androgen affects the production of EVs and nitric oxide (NO) in endothelial cells of rat penile corpus cavernosum. MATERIALS AND METHODS: Endothelial cells of rat penile corpus cavernosum were isolated and purified from 6-week-old healthy male Sprague Dawley (SD) rats. Endothelial cells were treated with different concentrations of dihydrotestosterone (DHT) in a cell culture medium as follows: no-androgen group (NA group, DHT 0 nmol/L), very-low androgen group (VLA group, DHT 0.1 nmol/L), low androgen group (LA group, DHT 1 nmol/L), and physiological concentrations androgen group (PA group, DHT 10 nmol/L). After 24 h, EVs of supernatant in each group were isolated and identified. The content of EVs and NO in the supernatant and the expression of CD9, CD63, TSG101, and eNOS in EVs were detected. RESULTS: Positive expression of CD9, CD63, TSG101, and eNOS was found in isolated EVs. The concentration of EVs was lower in the NA group compared with other groups (p < 0.01). The expression of eNOS and the concentration of NO was lower in the NA group than that in other groups (p < 0.05); it was lower in the VLA group than that in the LA group (p < 0.05) and lower in LA group than that in PA group (p < 0.05). When the concentration of DHT in endothelial cell culture medium ranged from 0 to 10 nmol/L, the concentration of DHT was positively correlated with the content of EVs and NO. CONCLUSION: Decrease in eNOS-expressing EVs is one mechanism of NO reduction in endothelial cells of rat corpus cavernosum caused by low androgen levels.
Subject(s)
Androgens/administration & dosage , Dihydrotestosterone/administration & dosage , Endothelial Cells/drug effects , Extracellular Vesicles/drug effects , Penis/drug effects , Animals , Drug Evaluation, Preclinical , Endothelial Cells/metabolism , Erectile Dysfunction/drug therapy , Extracellular Vesicles/metabolism , Male , Penis/metabolism , Primary Cell Culture , Rats, Sprague-DawleyABSTRACT
To clarify the direct effects of androgens, the changes in the hypothalamic levels of reproductive and appetite regulatory factors induced by chronic dihydrotestosterone (DHT) administration were evaluated in female rats. DHT treatment increased the BW and food intake of the ovariectomized rats, but not the estradiol (E2)-treated rats. DHT administration suppressed the expression of a hypothalamic anorexigenic factor. Although the kisspeptin (Kiss1) mRNA levels of the anterior hypothalamic block (the anteroventral periventricular nucleus, AVPV) were increased in the E2-treated rats, DHT administration did not affect the Kiss1 mRNA levels of the AVPV in the ovariectomized or E2-treated rats. Conversely, DHT administration reduced the Kiss1 mRNA levels of the posterior hypothalamic block (the arcuate nucleus, ARC) in the ovariectomized rats. Although the Kiss1 mRNA levels of the posterior hypothalamic block (ARC) were decreased in the E2-treated rats, DHT administration did not affect the Kiss1 mRNA levels of the ARC in these rats. Serum luteinizing hormone levels of these groups exhibited similar patterns to the Kiss1 mRNA levels of the ARC. These results showed that DHT affects the production of hypothalamic reproductive and appetite regulatory factors, and that these effects of DHT differ according to the estrogen milieu.
Subject(s)
Body Weight/drug effects , Dihydrotestosterone/administration & dosage , Estradiol/administration & dosage , Ovariectomy , Reproduction/drug effects , Animals , Arcuate Nucleus of Hypothalamus/chemistry , Arcuate Nucleus of Hypothalamus/drug effects , Arcuate Nucleus of Hypothalamus/metabolism , Eating/drug effects , Female , Hypothalamus/chemistry , Hypothalamus/drug effects , Hypothalamus/metabolism , Kisspeptins/genetics , RNA, Messenger/analysis , Rats , Rats, WistarABSTRACT
Precise spatiotemporal epigenetic regulation of the genome facilitates species-typical development; sexual differentiation of the brain by gonadal hormones and sex chromosomes causes extensive epigenetic reprogramming of many cells in the body, including the brain, and may indirectly predispose males and females to different psychiatric conditions. We and others have demonstrated sex differences in DNA methylation, as well as in the enzymes that form, or 'write', this epigenetic modification. However, while a growing body of evidence suggests that DNA methylation undergoes rapid turnover and is dynamically regulated in vivo, to our knowledge no studies have been done investigating whether sex differences exist in the epigenetic 'erasers' during postnatal development. Here we report sex differences in the expression of growth arrest and DNA damage inducible factor ß (Gadd45b), but not family members α (a) or γ (g), in the neonatal and juvenile rodent amygdala.
Subject(s)
Amygdala/growth & development , Amygdala/metabolism , Antigens, Differentiation/metabolism , Sex Characteristics , Amygdala/drug effects , Animals , Animals, Newborn , Antigens, Differentiation/genetics , Cell Cycle Proteins/metabolism , DNA Methylation/physiology , Dihydrotestosterone/administration & dosage , Dihydrotestosterone/metabolism , Estrogens/administration & dosage , Estrogens/metabolism , Female , Hormones/administration & dosage , Hormones/metabolism , Hypothalamus/drug effects , Hypothalamus/growth & development , Hypothalamus/metabolism , Intracellular Signaling Peptides and Proteins/metabolism , Male , Models, Animal , Nuclear Proteins/metabolism , Promoter Regions, Genetic/physiology , RNA, Messenger/metabolism , Rats, Sprague-Dawley , Testosterone/administration & dosage , Testosterone/metabolism , GADD45 ProteinsABSTRACT
The contribution of sex steroids to nutrient partitioning and energy balance during gonad development was studied in rainbow trout. Specifically, 19-mo old triploid (3N) female rainbow trout were fed treatment diets supplemented with estradiol-17ß (E2), testosterone (T), or dihydrotestosterone at 30-mg steroid/kg diet for a 1-mo period. Growth performance, nutrient partitioning, and expression of genes central to growth and nutrient metabolism were compared with 3N and age-matched diploid (2N) female fish consuming a control diet not supplemented with steroids. Only 2 N fish exhibited active gonad development, with gonad weights increasing from 3.7% to 5.5% of body weight throughout the study, whereas gonad weights in 3N fish remained at 0.03%. Triploid fish consuming dihydrotestosterone exhibited faster specific growth rates than 3N-controls (P < 0.05). Consumption of E2 in 3N fish reduced fillet growth and caused lower fillet yield compared with all other treatment groups (P < 0.05). In contrast, viscera fat gain was not affected by steroid consumption (P > 0.05). Gene transcripts associated with physiological pathways were identified in maturing 2N and E2-treated 3N fish that differed in abundance from 3N-control fish (P < 0.05). In liver these mechanisms included the growth hormone/insulin-like growth factor (IGF) axis (igf1, igf2), IGF binding proteins (igfbp1b1, igfbp2b1, igfbp5b1, igfbp6b1), and genes associated with lipid binding and transport (fabp3, fabp4, lpl, cd36), fatty acid oxidation (cpt1a), and the pparg transcription factor. In muscle, these mechanisms included reductions in myogenic gene expression (fst, myog) and the proteolysis-related gene, cathepsin-L, suggesting an E2-induced reduction in the capacity for muscle growth. These findings suggest that increased E2 signaling in the sexually maturing female rainbow trout alters physiological pathways in liver, particularly those related to IGF signaling and lipid metabolism, to partition nutrients away from muscle growth toward support of maturation-related processes. In contrast, the mobilization of viscera lipid stores appear to be mediated less by E2 and more by energy demands associated with gonad development. These findings improve the understanding of how steroids regulate nutrient metabolism to meet the high energy demands associated with gonad development during sexual maturation.
Subject(s)
Animal Nutritional Physiological Phenomena/drug effects , Animal Nutritional Physiological Phenomena/genetics , Gonadal Steroid Hormones/pharmacology , Oncorhynchus mykiss/growth & development , Oncorhynchus mykiss/metabolism , Triploidy , Animals , Diet , Dihydrotestosterone/administration & dosage , Dihydrotestosterone/blood , Estradiol/administration & dosage , Estradiol/blood , Female , Gene Expression/drug effects , Insulin-Like Growth Factor I/analysis , Muscles/metabolism , Oncorhynchus mykiss/genetics , Ovary/growth & development , Testosterone/administration & dosage , Testosterone/blood , Weight GainABSTRACT
Mating depends on the accurate detection of signals that convey species identity and reproductive state. In African clawed frogs, Xenopus, this information is conveyed by vocal signals that differ in temporal patterns and spectral features between sexes and across species. We characterized spectral sensitivity using auditory-evoked potentials (AEPs), commonly known as the auditory brainstem response, in males and females of four Xenopus species. In female X. amieti, X. petersii, and X. laevis, peripheral auditory sensitivity to their species own dyad-two, species-specific dominant frequencies in the male advertisement call-is enhanced relative to males. Males were most sensitive to lower frequencies including those in the male-directed release calls. Frequency sensitivity was influenced by endocrine state; ovariectomized females had male-like auditory tuning while dihydrotestosterone-treated, ovariectomized females maintained female-like tuning. Thus, adult, female Xenopus demonstrate an endocrine-dependent sensitivity to the spectral features of conspecific male advertisement calls that could facilitate mating. Xenopus AEPs resemble those of other species in stimulus and level dependence, and in sensitivity to anesthetic (MS222). AEPs were correlated with body size and sex within some species. A frequency following response, probably encoded by the amphibian papilla, might facilitate dyad source localization via interaural time differences.
Subject(s)
Auditory Perception/physiology , Endocrine System/physiology , Evoked Potentials, Auditory, Brain Stem/physiology , Sex Characteristics , Vocalization, Animal/physiology , Xenopus/physiology , Acoustic Stimulation/methods , Aminobenzoates/pharmacology , Androgens/administration & dosage , Anesthetics/pharmacology , Animals , Auditory Perception/drug effects , Body Weight , Dihydrotestosterone/administration & dosage , Endocrine System/drug effects , Evoked Potentials, Auditory, Brain Stem/drug effects , Female , Male , Ovariectomy , Species SpecificityABSTRACT
OBJECTIVE: Androgen excess in women is associated with visceral adiposity. However, little is known on the mechanism through which androgen promotes visceral fat accumulation. METHODS: To address this issue, female mice to chronic androgen excess using 5α-dihydrotestosterone (DHT) and studied the regulation of energy homeostasis was exposed. RESULTS: DHT induced a leptin failure to decrease body weight associated with visceral adiposity but without alterations in leptin anorectic action. This paralleled leptin's failure to upregulate brown adipose tissue expression of uncoupling protein-1, associated with decreased energy expenditure (EE). DHT decreased hypothalamic proopiomelanocortin (pomc) mRNA expression and increased POMC intensity in neuronal bodies of the arcuate nucleus while simultaneously decreasing the intensity of POMC projections to the dorsomedial hypothalamus (DMH). This was associated with a failure of the melanocortin 4 receptor agonist melanotan-II to suppress body weight. CONCLUSION: Taken together, these data indicate that androgen excess promotes visceral adiposity with reduced POMC neuronal innervation in the DMH, reduced EE but without hyperphagia.
Subject(s)
Adiposity/physiology , Androgens/administration & dosage , Androgens/blood , Dihydrotestosterone/administration & dosage , Dihydrotestosterone/blood , Intra-Abdominal Fat/drug effects , Adipose Tissue, Brown/drug effects , Adipose Tissue, Brown/metabolism , Androgens/adverse effects , Animals , Arcuate Nucleus of Hypothalamus/drug effects , Arcuate Nucleus of Hypothalamus/metabolism , Body Composition , Body Weight , Energy Metabolism , Female , Hyperphagia/pathology , Hypothalamus/drug effects , Hypothalamus/metabolism , Intra-Abdominal Fat/metabolism , Ion Channels/genetics , Ion Channels/metabolism , Leptin/blood , Mice , Mice, Inbred C57BL , Mitochondrial Proteins/genetics , Mitochondrial Proteins/metabolism , Obesity/metabolism , Peptides, Cyclic/metabolism , Pro-Opiomelanocortin/genetics , Pro-Opiomelanocortin/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Receptor, Melanocortin, Type 4/genetics , Receptor, Melanocortin, Type 4/metabolism , Uncoupling Protein 1 , Up-Regulation , alpha-MSH/analogs & derivatives , alpha-MSH/metabolismABSTRACT
Our previous studies showed that streptozotocin (STZ)-induced diabetic male rats have increased estradiol and decreased testosterone levels that correlate with renal injury (Xu Q, Wells CC, Garman GH, Asico L, Escano CS, Maric C. Hypertension 51: 1218-1224, 2008). We further showed that either supplementing dihydrotestosterone (DHT) or inhibiting estradiol biosynthesis in these diabetic rats was only partially renoprotective (Manigrasso MB, Sawyer RT, Marbury DC, Flynn ER, Maric C. Am J Physiol Renal Physiol 301: F634-F640, 2011; Xu Q, Prabhu A, Xu S, Manigrassso MB, Maric C. Am J Physiol 297: F307-F315, 2009). The aim of this study was to test the hypothesis that the combined therapy of DHT supplementation and inhibition of estradiol synthesis would afford better renoprotection than either treatment alone. The study was performed in 12-wk-old male nondiabetic (ND), STZ-induced diabetic (D), and STZ-induced diabetic rats that received the combined therapy of 0.75 mg/day of DHT along with 0.15 mg · kg(-1) · day(-1) of an aromatase inhibitor, anastrozole (Dta), for 12 wk. Treatment with the combined therapy resulted in attenuation of albuminuria by 84%, glomerulosclerosis by 55%, and tubulointerstitial fibrosis by 62%. In addition, the combined treatment decreased the density of renal cortical CD68-positive cells by 70% and decreased protein expression of transforming growth factor-ß protein expression by 60%, collagen type IV by 65%, TNF-α by 55%, and IL-6 by 60%. We conclude that the combined treatment of DHT and blocking aromatase activity in diabetic male STZ-induced diabetic rats provides superior treatment than either treatment alone in the prevention of diabetic renal disease.
Subject(s)
Albuminuria/prevention & control , Aromatase Inhibitors/pharmacology , Aromatase/drug effects , Diabetes Mellitus, Experimental/complications , Diabetic Nephropathies/prevention & control , Dihydrotestosterone/therapeutic use , Nitriles/pharmacology , Triazoles/pharmacology , Albuminuria/epidemiology , Albuminuria/metabolism , Anastrozole , Animals , Collagen Type IV/metabolism , Diabetes Mellitus, Experimental/chemically induced , Diabetic Nephropathies/epidemiology , Diabetic Nephropathies/metabolism , Dietary Supplements , Dihydrotestosterone/administration & dosage , Disease Models, Animal , Estrogen Receptor alpha/metabolism , Incidence , Male , Rats , Rats, Sprague-Dawley , Receptors, Androgen/metabolism , Streptozocin/adverse effects , Tumor Necrosis Factor-alpha/metabolismABSTRACT
Prostate cancer usually responds to androgen deprivation therapy, although the response in metastatic disease is almost always transient and tumors eventually progress as castration-resistant prostate cancer (CRPC). CRPC continues to be driven by testosterone or dihydrotestosterone from intratumoral metabolism of 19-carbon adrenal steroids from circulation, and/or de novo intratumoral steroidogenesis. Both mechanisms require 3beta-hydroxysteroid dehydrogenase (3betaHSD) metabolism of Delta(5)-steroids, including dehydroepiandrosterone (DHEA) and Delta(5)-androstenediol (A5diol), to testosterone. In contrast, reports that DHEA and A5diol directly activate the androgen receptor (AR) suggest that 3betaHSD metabolism is not required and that 3betaHSD inhibitors would be ineffective in the treatment of CRPC. We hypothesized that activation of AR in prostate cancer by DHEA and A5diol requires their conversion via 3betaHSD to androstenedione and testosterone, respectively. Here, we show that DHEA and A5diol induce AR chromatin occupancy and AR-regulated genes. Furthermore, we show that Delta(5)-androgens undergo 3beta-dehydrogenation in prostate cancer and that induction of AR nuclear translocation, AR chromatin occupancy, transcription of PSA, TMPRSS2, and FKBP5, as well as cell proliferation by DHEA and A5diol, are all blocked by inhibitors of 3betaHSD. These findings demonstrate that DHEA and A5diol must be metabolized by 3betaHSD to activate AR in these models of CRPC. Furthermore, this work suggests that 3betaHSD may be exploited as a pharmacologic target in the treatment of CRPC.
Subject(s)
17-Hydroxysteroid Dehydrogenases/antagonists & inhibitors , Antineoplastic Agents/administration & dosage , Carcinoma/drug therapy , Prostatic Neoplasms/drug therapy , 17-Hydroxysteroid Dehydrogenases/metabolism , 17-Hydroxysteroid Dehydrogenases/physiology , Antineoplastic Agents/pharmacology , Carcinoma/genetics , Carcinoma/pathology , Carcinoma/surgery , Cell Line, Tumor , Cell Nucleus/drug effects , Cell Nucleus/metabolism , Dehydroepiandrosterone/metabolism , Dihydrotestosterone/administration & dosage , Dihydrotestosterone/analogs & derivatives , Dihydrotestosterone/pharmacology , Dose-Response Relationship, Drug , Drug Delivery Systems , Drug Evaluation, Preclinical , Enzyme Inhibitors/administration & dosage , Enzyme Inhibitors/pharmacology , Humans , Male , Models, Biological , Orchiectomy , Prostatic Neoplasms/genetics , Prostatic Neoplasms/pathology , Prostatic Neoplasms/surgery , Receptors, Androgen/metabolism , Treatment FailureSubject(s)
3-Hydroxysteroid Dehydrogenases/antagonists & inhibitors , Aldosterone/metabolism , Blood Pressure/drug effects , Dihydrotestosterone/analogs & derivatives , Enzyme Inhibitors/administration & dosage , Hypertension/enzymology , Hypothalamus/enzymology , Receptors, Mineralocorticoid/metabolism , Steroid Hydroxylases/antagonists & inhibitors , 3-Hydroxysteroid Dehydrogenases/metabolism , Aldosterone/blood , Animals , Corticosterone/metabolism , Cytochrome P-450 CYP11B2 , Dihydrotestosterone/administration & dosage , Heart Rate , Hypertension/etiology , Hypertension/physiopathology , Hypertension/prevention & control , Hypothalamus/drug effects , Mineralocorticoid Receptor Antagonists/administration & dosage , Rats , Rats, Inbred Dahl , Sodium/cerebrospinal fluid , Sodium Chloride, Dietary/metabolism , Steroid Hydroxylases/metabolismABSTRACT
Chronic anabolic-androgenic steroid (AAS) treatment during adolescence facilitates offensive aggression in male Syrian hamsters (Mesocricetus auratus). Serotonin (5-HT) modulates aggressive behavior and has been shown to be altered after chronic treatment with AAS. Furthermore, 5-HT type 2 receptors have been implicated in the control of aggression. For example, treatment with 5-HT(2A) receptor antagonists suppress the generation of the offensive aggressive phenotype. However, it is unclear whether these receptors are sensitive to adolescent AAS exposure. The current study assessed whether treatment with AAS throughout adolescence influenced the immunohistochemical localization of 5-HT(2A) in areas of the hamster brain implicated in the control of aggression. Hamsters were administered AAS (5.0 mg/kg) each day throughout adolescence, scored for offensive aggression, and then examined for differences in 5-HT(2A)-immunoreactivity (5-HT(2A)-ir). When compared with non-aggressive oil-treated controls, aggressive AAS-treated hamsters showed significant increases in 5-HT(2A)-ir fibers in the lateral portion of the anterior hypothalamus (LAH). Further analysis revealed that AAS treatment also produced a significant increase in the number of cells expressing 5-HT(2A)-ir in the LAH. Together, these results support a role for altered 5-HT(2A) expression and further implicate the LAH as a central brain region important in the control of adolescent AAS-induced offensive aggression.
Subject(s)
Aggression/drug effects , Anabolic Agents/pharmacology , Androgens/pharmacology , Hypothalamus/drug effects , Receptor, Serotonin, 5-HT2A/metabolism , Aging , Anabolic Agents/administration & dosage , Androgens/administration & dosage , Animals , Cricetinae , Delayed-Action Preparations , Dihydrotestosterone/administration & dosage , Dihydrotestosterone/pharmacology , Drug Administration Schedule , Hypothalamus/metabolism , Male , Mesocricetus , Nandrolone/administration & dosage , Nandrolone/pharmacology , Receptor, Serotonin, 5-HT2A/drug effects , Testosterone/administration & dosage , Testosterone/analogs & derivatives , Testosterone/pharmacologyABSTRACT
Cushing's disease caused by pituitary corticotroph adenoma in dogs is usually treated by medical treatment, and the efficacy of this treatment has been reported. However, controversy remains as to whether reduced negative feedback through the inhibition of cortisol secretion, similar to Nelson's syndrome, may appear as an adverse effect. The purpose of this study was to investigate the effect of reduced negative feedback through the inhibition of cortisol secretion by daily trilostane administration on the pituitary-adrenal axis in clinically normal dogs. Dogs were administered 5mg/kg trilostane twice a day every day for 8 weeks (n=8) or 16 weeks (n=3). After the initiation of trilostane administration, plasma adrenocorticotropic hormone (ACTH) concentrations were increased remarkably. As assessed by magnetic resonance imaging (MRI) during administration, the pituitary became enlarged. After trilostane administration, the cytoplasmic areas of the pituitary corticotrophs were increased and the ratio of pituitary corticotrophs to all cells in the anterior lobe was greater in the trilostane-treated dogs than that in untreated animals. In addition, histological examinations revealed bilateral adrenal cortical hyperplasia. Using real-time PCR quantification, the expression of proopiomelanocortin (POMC) mRNA in the pituitary and ACTH receptor (ACTH-R) mRNA in the adrenal gland was greater in the dogs treated with trilostane than in untreated dogs. These results indicate that reduced negative feedback induced hyperfunction of the pituitary corticotrophs and pituitary enlargement in healthy dogs. These changes suggest that the inhibition of cortisol secretion by trilostane may increase the risk for accelerating the growth of corticotroph adenomas in dogs with Cushing's disease.
Subject(s)
Antineoplastic Agents/adverse effects , Dihydrotestosterone/analogs & derivatives , Dogs , Hydrocortisone/antagonists & inhibitors , Hypothalamus/drug effects , Pituitary Gland/drug effects , Adrenal Glands/chemistry , Adrenal Glands/drug effects , Adrenal Glands/pathology , Adrenocorticotropic Hormone/blood , Animals , Antineoplastic Agents/administration & dosage , Corticotrophs/drug effects , Corticotrophs/ultrastructure , Dihydrotestosterone/administration & dosage , Dihydrotestosterone/adverse effects , Feedback, Physiological/drug effects , Female , Hydrocortisone/metabolism , Hyperplasia , Magnetic Resonance Imaging , Male , Pituitary Gland/chemistry , Pituitary Gland/pathology , Pro-Opiomelanocortin/genetics , RNA, Messenger/analysis , Receptors, Corticotropin/geneticsSubject(s)
Acaridae , Blepharitis/drug therapy , Blepharitis/etiology , Conjunctivitis/drug therapy , Conjunctivitis/etiology , Dihydrotestosterone/analogs & derivatives , Mite Infestations/complications , Mite Infestations/drug therapy , Anti-Infective Agents/administration & dosage , Anti-Infective Agents/therapeutic use , Dihydrotestosterone/administration & dosage , Dihydrotestosterone/therapeutic use , Drug Combinations , Humans , Insecticides/administration & dosage , Insecticides/therapeutic use , Metronidazole/administration & dosage , Metronidazole/therapeutic use , Ointments , Zinc/administration & dosage , Zinc/therapeutic useABSTRACT
Sex hormone binding globulin (SHBG) is produced in brain where it is often co-localized with oxytocin. Infusions of SHBG into the medial preoptic area-anterior hypothalamus facilitate female sexual receptivity. SHBG has receptors on plasma membranes of the prostate gland where binding of the 5alpha-reduced androgen dihydrotestosterone (DHT) by SHBG acts as an antagonist on SHBG receptors. This study attempted to determine whether pre-coupling DHT to SHBG would inhibit SHBG-induced facilitation of female sexual receptivity. Ovariectomized rats were injected daily with 0.75 microg estradiol benzoate for 3 days. On the fourth day after a pre-infusion baseline behavioral test animals were infused with 1 microl per side through bilateral cannulae with SHBG (1.77x10(-6) M), SHBG coupled to DHT (SHBG-DHT; 1.66x10(-6) M DHT), with DHT alone or with artificial cerebrospinal fluid vehicle. As before, SHBG significantly increased female sexual receptivity when infused into the medial preoptic area-anterior hypothalamus. Rats infused with SHBG-DHT had significantly lower sexual receptivity. Therefore, whereas SHBG in the medial preoptic area facilitated female sexual behavior, SHBG coupled to DHT did not. DHT itself did not significantly affect sexual receptivity. Pre-coupling DHT to SHBG eliminated the facilitative effect of SHBG on female sexual receptivity just as DHT inhibits SHBG activity at prostate SHBG receptors suggesting that central receptors for SHBG are similar to those demonstrated in the periphery.
Subject(s)
Dihydrotestosterone/metabolism , Sex Hormone-Binding Globulin/metabolism , Sex Hormone-Binding Globulin/pharmacology , Sexual Behavior, Animal/drug effects , Animals , Catheterization , Dihydrotestosterone/administration & dosage , Drug Administration Routes , Drug Administration Schedule , Estradiol/analogs & derivatives , Estradiol/pharmacology , Female , Hypothalamus/drug effects , Hypothalamus/physiology , Ovariectomy , Posture , Preoptic Area/drug effects , Preoptic Area/physiology , Rats , Rats, Sprague-Dawley , Sex Hormone-Binding Globulin/administration & dosage , Sexual Behavior, Animal/physiologyABSTRACT
The neurodegenerative plaques of Alzheimer's disease (AD) are characterized by a self-sustaining acute-phase reaction in which both interleukin-1 (IL-1) and interleukin-6 (IL-6) are up-regulated. The fact that IL-6 is detectable in early stage diffuse plaques encourages the speculation that the acute-phase process is crucial to the pathogenesis of AD. The epidemiological association of AD with estrogen deficiency, as well as with various disorders characterized by vascular endotheliopathy, suggest a protective role for vascular nitric oxide (NO). NO has an autocrine anti-inflammatory impact on endothelium, owing in part to antagonism of NF-kappaB activity; since induction of IL-6 is dependent on NF-kappaB, this may explain recent evidence that NO inhibits macrophage IL-6 production. It is reasonable to postulate that, analogously, cerebrovascular NO decreases IL-6 production in the brain. Vascular NO may also have direct neuroprotective activity. Estrogen, in addition to promoting vascular NO synthesis, can block IL-6 production by a more direct mechanism in cells expressing estrogen receptors; since such receptors have been reported in brain glia and astrocytes, estrogen has the potential to limit brain IL-1 activity. Testosterone likewise can inhibit IL-6 induction in androgen-responsive cells, which may include brain glia and astrocytes. Since fish oil and gamma linolenic acid (GLA) suppress IL-1 production by stimulated monocytes, they conceivably could exert this effect in the brain as well; the comparatively low prevalence of AD in elderly Japanese is intriguing in this regard. These considerations suggest that a healthy cerebrovascular endothelium, sex hormone activity, and dietary fish oil/GLA may slow or prevent AD onset by dampening acute-phase mechanisms in the brain.
Subject(s)
Alzheimer Disease/prevention & control , Fish Oils/therapeutic use , Hormone Replacement Therapy , Interleukin-1/antagonists & inhibitors , Interleukin-6/antagonists & inhibitors , Nitric Oxide/physiology , Blood Vessels/metabolism , Dihydrotestosterone/administration & dosage , Dihydrotestosterone/pharmacology , Down-Regulation/drug effects , Estradiol/administration & dosage , Estradiol/pharmacology , Fish Oils/pharmacology , Humans , Interleukin-1/biosynthesis , Interleukin-6/biosynthesisABSTRACT
Testosterone (T) inhibits LH secretion partly by acting at unknown sites within the brain to inhibit GnRH secretion. We tested the hypothesis that the preoptic area (POA) and arcuate-ventromedial region (ARC/VMR), areas rich in androgen and estrogen (E) receptors, are neural sites at which T and the T metabolites, dihydrotestosterone (DHT) and estrogen (E), act to suppress LH secretion. Bilateral guide cannulae were surgically implanted into either the POA or ARC/VMR of castrated male sheep. Experiments were conducted under a long day photoperiod to maximize the inhibitory effect of the steroids. In Exp 1, all sheep (n = 6/site) sequentially received bilateral implants of cholesterol (CHOL), T, or E at each site. Jugular blood samples were taken at 10-min intervals for 4 h both immediately before implant insertion and 5 days later. In Exp 2, all sheep (n = 6/site) sequentially received bilateral implants of CHOL, DHT, or E at each site according to a latin square design. Blood samples were taken before and 7 days after implant insertion. In Exp 3, which followed the same design as Exp 2, implants of E, T, or DHT were placed only in the ARC/VMR. In the final experiment, the effects of T and CHOL implants in the ARC/VMR were compared. Neither T, DHT, nor CHOL implants at either site affected LH secretion. In contrast, E treatment in the ARC/VMR suppressed mean plasma LH levels (P < 0.01), primarily due to an increase in interpulse interval (P < 0.01). Estrogen implants in the POA caused a small, but nonsignificant (P > 0.05), decrease in mean LH levels in the first experiment and an increase in LH interpulse interval (P < 0.05) in the second experiment. These results suggest that the ARC/VMR and possibly the POA are sites at which E acts to reduce GnRH secretion in male sheep.
Subject(s)
Dihydrotestosterone/pharmacology , Estrogens/pharmacology , Hypothalamus/drug effects , Luteinizing Hormone/metabolism , Sheep/physiology , Testosterone/pharmacology , Animals , Arcuate Nucleus of Hypothalamus/drug effects , Arcuate Nucleus of Hypothalamus/physiology , Cholesterol/administration & dosage , Cholesterol/pharmacology , Diffusion , Dihydrotestosterone/administration & dosage , Drug Implants , Estrogens/administration & dosage , Feedback , Hypothalamus/physiology , Hypothalamus, Middle/drug effects , Hypothalamus, Middle/physiology , Male , Preoptic Area/drug effects , Preoptic Area/physiology , Testosterone/administration & dosageABSTRACT
To characterize the effect of androgens on the hypothalamo-pituitary-adrenal (HPA) axis we examined the regulation of corticotropin-releasing hormone (CRH) following gonadectomy and hormone replacement. Three-month-old male Fischer 344 (F344) rats were gonadectomized (GDX) or sham GDX. Control animals remained intact. Animals were sacrificed 1, 4, 7, 10, or 21 days following surgery. GDX rats had significantly elevated (p < 0.05) levels of hypothalamic CRH 21 days after surgery compared to intact and sham-operated rats. In a second study, 3-month-old male F344 rats were GDX and treated with the non-aromatizable androgen, dihydrotestosterone (DHT), using a Silastic capsule containing crystalline DHT propionate subcutaneously implanted in each animal's back. Control animals were GDX and sham-treated or left intact (INT). Three weeks following gonadectomy, CRH levels in the hypothalamus of GDX rats showed a significant increase (p < 0.05) compared to intact animals. DHT treatment, beginning at the time of gonadectomy prevented this increase. CRH or arginine vasopressin (AVP) immunoreactivity was examined using immunocytochemistry. The number of CRH-immunoreactive (IR) cells in the paraventricular nucleus (PVN) of GDX, DHT-treated animals was significantly decreased (p < 0.05) compared to GDX rats. No differences were seen between treatment groups in CRH-IR cell numbers in the bed nucleus of the stria terminalis or the central amygdaloid nucleus or in AVP-IR cell numbers in the PVN. These data demonstrate that long-term castration increases hypothalamic CRH content and CRH-IR cell numbers in the PVN by removal of an androgen-dependent repression.
Subject(s)
Androgens/pharmacology , Corticotropin-Releasing Hormone/metabolism , Hypothalamus/metabolism , Orchiectomy , Androgens/administration & dosage , Animals , Corticotropin-Releasing Hormone/immunology , Dihydrotestosterone/administration & dosage , Dihydrotestosterone/pharmacology , Drug Implants , Hypothalamus/cytology , Hypothalamus/drug effects , Immunohistochemistry , Iodine Radioisotopes , Male , Paraventricular Hypothalamic Nucleus/cytology , Paraventricular Hypothalamic Nucleus/drug effects , Paraventricular Hypothalamic Nucleus/metabolism , Radioimmunoassay , Rats , Rats, Inbred F344ABSTRACT
Biosynthesis of the neuropeptide vasopressin (VP) in extrahypothalamic neurons is dependent on circulating levels of testosterone (T). However, the mechanism by which endogenous or peripherally administered T induces VP gene expression in the brain has not been established. This study investigated the effects of androgens and estrogen in the steroid-dependent expression of VP mRNA in the bed nucleus of the stria terminalis (BNST). Testosterone, estrogen, and the T metabolite, dihydrotestosterone (DHT), were either peripherally administered or locally implanted in cannula into the BNST of castrated male rats to determine whether these steroids influence VP gene expression through a local effect within the nucleus itself. The results indicate that T does act locally within the BNST, since complete restoration of VP mRNA levels occurred in BNST neurons in the vicinity of T-containing cannulas but not on the contralateral side. In addition, both DHT and estrogen were partially effective in stimulating VP gene expression in the BNST, and in combination, synergized to produce the full complement of VP gene expression induced by T itself.
Subject(s)
Dihydrotestosterone/metabolism , Hypothalamus/drug effects , RNA, Messenger/drug effects , Sex Characteristics , Testosterone/physiology , Vasopressins/genetics , Animals , Dihydrotestosterone/administration & dosage , Drug Implants , Estrogens/administration & dosage , Hypothalamus/metabolism , Male , RNA, Messenger/biosynthesis , Rats , Testosterone/administration & dosageABSTRACT
Estrogens are produced locally from androgen precursors by cells within the hypothalamus and preoptic area (POA). The activity of the aromatase enzyme complex responsible for this intracellular conversion is controlled by gonadal steroids. The purpose of this study was to determine: (1) whether estrogen acts together with androgen to regulate aromatase activity (AA) and (2) whether nuclear androgen receptor levels are increased after exposure to combined treatment with estradiol benzoate (EB) and dihydrotestosterone (DHT). Thus, adult male rats were castrated and treated for 1 week with either vehicle (0.1 ml sesame oil, s.c.), EB (2 micrograms/day), testosterone (3-cm Silastic implant), DHT (3-cm Silastic implant) or EB + DHT. These treatments produced hormone levels in the physiologic range. We found that both testosterone and DHT significantly stimulated AA (p less than 0.05 vs. castrated rats). However, testosterone induced AA significantly more than DHT in the POA (p less than 0.05; castrated + testosterone vs. castrated + DHT). EB alone did not affect AA but synergized with DHT to stimulate AA in the POA to levels equivalent with the testosterone-treated group. By comparison, EB alone did not enhance the induction of AA by DHT in the hypothalamus. Combined treatment with EB and DHT had no effect on the concentrations of nuclear androgen receptors in either tissue suggesting that the effect of EB was not mediated through an androgen receptor mechanism. These results suggest that both androgens and estrogens play a physiologic role in the control of estrogen formation in the rat brain. Furthermore, the anatomical specificity that we observed indicates that critical differences in enzyme responsiveness are present in different areas of the brain.
Subject(s)
Aromatase/biosynthesis , Brain/enzymology , Dihydrotestosterone/pharmacology , Estradiol/pharmacology , Animals , Cell Nucleus/metabolism , Dihydrotestosterone/administration & dosage , Drug Synergism , Enzyme Induction/drug effects , Estradiol/administration & dosage , Hypothalamus/enzymology , Hypothalamus/ultrastructure , Male , Orchiectomy , Preoptic Area/enzymology , Preoptic Area/ultrastructure , Rats , Rats, Inbred Strains , Receptors, Androgen/metabolism , Testosterone/administration & dosage , Testosterone/pharmacologyABSTRACT
The objectives of this investigation were to evaluate the release of testosterone (T) and dihydrotestosterone (DHT) from nonimpregnated and polylactic acid (PLA) impregnated ALCAP ceramic reservoirs implanted in rats, and to study the effects of delivered androgens on the reproductive system of male rats. A total of 120 Sprague-Dawley albino male rats were distributed equally into three groups Two ALCAP capsules, one nonimpregnated and the other impregnated with PLA, were implanted into each rat in groups I and II. Capsules implanted into group I rats were loaded with a mixture of 20 mg T and 20 mg DHT. Group II rats were implanted with two empty capsules (sham group), and group III animals served as unimplanted controls. Eight rats from each group were euthanized at the end of 3, 6, 9, and 12 months following the implantation of the ceramics. No significant change in the weights of vital organs of rats was observed among any of the three different groups. Vas deferens and epididymal fluid were devoid of normal spermatozoa within 3 months of implanting the steroid-containing ceramics. Testicular weights decreased significantly in the rats implanted with ALCAP containing steroids and the seminiferous tubules became oligospermic after 1 month and azoospermic after 3 months. The data collected in this study suggest that (1) ALCAP ceramic capsules are capable of delivering T and DHT in combined form, and (2) T and DHT delivered by ALCAP capsules can be used effectively to regulate spermatogenesis in rats.
Subject(s)
Aluminum Oxide , Dihydrotestosterone/administration & dosage , Genitalia, Male/drug effects , Oxides , Phosphorus , Prostheses and Implants , Spermatozoa/drug effects , Testosterone/administration & dosage , Animals , Dihydrotestosterone/pharmacology , Drug Implants , Genitalia, Male/anatomy & histology , Male , Organ Size/drug effects , Rats , Rats, Inbred Strains , Sperm Count/drug effects , Sperm Motility/drug effects , Spermatozoa/ultrastructure , Testosterone/pharmacologyABSTRACT
Two experiments were conducted to identify sites in the female rat brain at which dihydrotestosterone acts to inhibit estradiol-induced feminine sexual behavior. 27 gauge cannulae containing either crystalline dihydrotestosterone propionate (DHTP) or cholesterol were implanted unilaterally into the lateral septum, preoptic area-anterior hypothalamic area, ventromedial nucleus of the hypothalamus or caudate putamen. In experiment 1, rats were given stereotaxic implants of steroids prior to being injected daily with estradiol benzoate (EB; 0.5 microgram/100 g body weight) and tested for sexual receptivity. In experiment 2, animals were injected daily with EB (0.9 microgram/100 body weight) and tested for sexual receptivity prior to and after stereotaxic implantation of steroids. In both experiments significant reductions in lordotic behavior were obtained only with lateral septal implants of DHTP.